| Active ingredient (INN) | Trastuzumab |
|---|---|
| Brand names | Herzuma, Kanjinti, Herceptin, Trazimera |
| ATC level 5 | L01FD01 |
| ATC level 4 | L01FD |
| Drug class | Anti-HER2 monoclonal antibody |
| Therapeutic category | Oncology/Immunology |
| Strength | 150mg · 440mg |
| Dosage form | powder for infusion |
| Route of administration | intravenous |
| WHO Essential Medicine | Yes (2023) |
| Controlled substance | No |
| Marketing-authorisation holders | Amgen Australia Pty Ltd, Roche Products Pty Ltd, Cipla Australia Pty Ltd, AstraZeneca Pty Ltd +2 more |
| Registrations on file | 20 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| HERZUMA trastuzumab | 150 mg | — | 🇦🇺 AU | — | Active |
| OGIVRI trastuzumab | 150 mg | — | 🇦🇺 AU | — | Active |
| KANJINTI trastuzumab | 150 mg | — | 🇦🇺 AU | Amgen Australia Pty Ltd | Active |
| KANJINTI trastuzumab | 60 mg | — | 🇦🇺 AU | Amgen Australia Pty Ltd | Active |
| PHESGO SC pertuzumab | 600 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| PHESGO SC pertuzumab | 1200mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| TRASTUCIP trastuzumab | 150 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| ENHERTU trastuzumab deruxtecan | 100 mg | — | 🇦🇺 AU | AstraZeneca Pty Ltd | Active |
| TUZUCIP trastuzumab | 150 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| HERZUMA trastuzumab | 440 mg | — | 🇦🇺 AU | — | Active |
| HERCEPTIN trastuzumab | 150mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| HERCEPTIN trastuzumab | 60mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| KADCYLA trastuzumab emtansine | 100 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| KADCYLA trastuzumab emtansine | 160 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| HERCEPTIN SC trastuzumab | 600mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |